Search Bar & Filters
Found 93 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are studying a new vaccine called V118C to help prevent pneumococcal disease, which is caused by Streptococcus pneumoniae bacteria and can lead to infections in the lungs or other parts of the body. This trial focuses on toddlers and infants to evaluate the safety and tolerability of V118C. The study is a Phase 1, randomized, double-blind trial comparing V118C with an existing pneumococcal vaccine called PCV20 in children. The study has two stages. Stage 1 includes toddlers aged 12 to 15 months who have completed a 3-dose infant series of PCV20 these participants receive a single 0.5 mL injection of either V118C or PCV20. Stage 2 enrolls infants around 2 months old who receive four doses of either V118C or PCV20 at 2, 4, 6, and 12 months of age. All doses are given by intramuscular injection. The study monitors participants in both stages for up to 12 months after vaccination. During the trial, researchers will track immediate and longer-term side effects, both at the injection site and systemically, for up to one year post-vaccination. They will also measure immune responses using blood tests to assess antibody levels against pneumococcal bacteria. Participants will have scheduled visits for vaccinations and follow-up assessments to evaluate safety, immune response, and tolerability of the vaccines over the study period.
Actively Recruiting
Researchers are evaluating the safety, reliability, reproducibility, and accuracy of the Canary canturioTM tibial extension in patients who have undergone total knee arthroplasty TKA due to knee osteoarthritis. This observational study compares outcomes between patients receiving the Zimmer Persona Personalized Knee System with the Canary canturioTM tibial extension and those receiving the Zimmer Persona system with a standard 14 mm 30 mm stem extension. The study aims to monitor safety risks and gait performance over five years post-TKA. Participants are divided into two groups one with the Canary canturioTM tibial extension and one with a standard stem extension. Safety endpoints include revision surgeries, loosening, fractures, and radiologic changes within five years after surgery. Secondary endpoints assess data collection on step counts and gait parameters, as well as patient-reported pain, knee function, and quality of life. A subgroup of patients will have detailed gait lab assessments at one and two years post-TKA. During the study, participants will be monitored for adverse events and their gait will be tracked using wearable technology to collect step count and walking data. Patient-reported outcomes such as pain scores and quality of life questionnaires will be completed regularly. The study lasts five years from the time of knee replacement surgery, with continuous data collection and periodic evaluations to assess the performance and safety of the knee systems.
Actively Recruiting
This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.
Actively Recruiting
Researchers are evaluating the inhalation suspension of ensifentrine, given twice daily via a standard jet nebulizer, for its effects on people with non-cystic fibrosis bronchiectasis NCFBE. This randomized, double-blind, placebo-controlled Phase II study aims to assess the safety and efficacy of ensifentrine compared to placebo over up to 52 weeks. The main focus is to see how ensifentrine affects lung flare-ups, symptoms, and quality of life in participants who continue their standard care. Participants will be randomly assigned to receive either 3 mg of nebulized ensifentrine or a matching placebo, both administered twice daily through a jet nebulizer for up to 52 weeks. Neither participants nor study staff will know which treatment is given. Some participants may finish earlier if the study ends after the last participant completes the 24-week visit. This trial compares the study drug to placebo while all participants receive their usual care. During the study, participants will be monitored regularly with lung function tests, symptom questionnaires, and quality of life assessments at baseline and at several points up to 24 weeks and through study completion. Researchers will measure the rate of lung exacerbations and track adverse events for up to 52 weeks. Additional pharmacokinetic tests will be done in a sub-study. Participants will be expected to perform spirometry and provide sputum samples, and their medication adherence and safety will be closely followed throughout the study period.
Actively Recruiting
Researchers are studying the safety and effectiveness of zenagamtide compared to semaglutide for treating adults with excess body weight. This Phase 3 trial focuses on participants with overweight or obesity to evaluate how these treatments help with weight loss. Participants are randomly assigned to one of three groups one receiving zenagamtide plus a placebo matching semaglutide, another receiving a lower dose of semaglutide plus a placebo matching zenagamtide, and the last group receiving a higher dose of semaglutide plus a placebo matching zenagamtide. All injections are given subcutaneously once weekly using pre-filled pen injectors in the thigh, abdomen, or upper arm. Participants also follow a reduced-calorie diet and increase physical activity throughout the study. During the 84-week study period, participants will be regularly monitored for changes in body weight and waist circumference. The main outcome is the relative change in body weight from the start to week 84. Safety and adherence will be assessed through scheduled visits where injections, diet, and exercise are reviewed. The study lasts until October 2028, with ongoing evaluations at specific intervals to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the drug Galvokimig compared to a placebo to see how it affects the time until the first acute worsening exacerbation of chronic obstructive pulmonary disease COPD in people with moderate-to-severe COPD who also have chronic bronchitis. This Phase 2 study focuses on participants aged 40 to 80 with a history of COPD exacerbations and chronic bronchitis symptoms. Participants are randomly assigned to receive one of two predefined doses of Galvokimig or a matching placebo. The study treatment is given as a solution for injection over a period ranging from 24 to 52 weeks. The purpose is to assess the drugs effect on reducing the frequency and timing of COPD exacerbations during this treatment phase. During the study, participants will be monitored regularly to measure lung function, quality of life related to respiratory health, and the number and severity of COPD exacerbations. Safety is closely followed by tracking adverse events up to 60 weeks. The main outcome is the time until the first moderate or severe COPD exacerbation, with additional assessments including lung function tests and patient questionnaires. Total study participation may last up to about 60 weeks.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating a new drug called IDRX-42 also known as GSK6042981 for treating adults with metastatic or surgically unresectable Gastrointestinal Stromal Tumors GIST. This study compares IDRX-42 to sunitinib in participants whose disease progressed or who could not tolerate the drug imatinib, which is used as first-line treatment. The study aims to determine if IDRX-42 works well and is safe for these patients. Participants whose disease worsens after receiving sunitinib may switch to IDRX-42 if they meet additional criteria. Participants will be randomly assigned to receive either IDRX-42 or sunitinib. Both drugs will be administered as part of the treatment. If a participants disease worsens on sunitinib, they may have the option to cross over to IDRX-42 based on the investigators decision and eligibility. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be closely monitored for how long they live without disease progression, overall survival, response to treatment, and quality of life using questionnaires. Blood samples will be taken to measure drug levels. Researchers will also track side effects and any changes in symptoms over time. The main outcome measured is progression-free survival for up to about 130 weeks, with some assessments continuing up to approximately 261 weeks. The total study duration extends until late 2030.
1-10 of 93
1